This institutional audit was conducted to analyze the surgical and survival outcomes in advanced epithelial ovarian cancers treated with neoadjuvant chemotherapy and interval debulking surgery.
Clinical records of patients of advanced epithelial ovarian cancers treated between January, 2011, and December, 2014, were retrospectively reviewed. Standard demographics, disease-related factors and treatment-related outcomes were analyzed.
A total of 100 patients were included for analysis. A majority (97%) received paclitaxel and carboplatin in the neoadjuvant setting. The number of cycles of NACT did not affect the status of residual disease after IDS (P = 0.307). At a median follow-up of 69 months, the median PFS was 17.5 months (0–89) and median OS was 32 months (5–89). A chemotherapy response score of 3 was significantly associated with an improved PFS (P = 0.032*). No significant difference in PFS was noted with respect to the number of cycles of NACT; however, a trend was observed in favor of ≤ 3 cycles (P = 0.218). On subset analysis, patients with stage IIIC disease showed a trend towards better PFS with ≤ 3 cycles of NACT, though not statistically significant (P = 0.075). Also, no difference in PFS was noted if the total number of chemotherapy cycles was increased beyond 6 (P = 0.309).
The survival outcomes reported here are consistent with most results published in the literature. CRS is an important prognostic biomarker. Increasing the number of chemotherapy cycles beyond 6 does not affect survival. No definite conclusion could, however, be drawn with respect to the ideal number of NACT cycles and needs further evaluation.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.
Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer. 2012;22(3):367–71.
Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.
Yang L, Zhang B, Xing G, Du J, Yang B, Yuan Q, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome. PLoS ONE. 2017;12(10):e0186725.
Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.
Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33.
Altman AD, McGee J, May T, Lane K, Lu L, Xu W, et al. Neoadjuvant chemotherapy and chemotherapy cycle number: a national multicentre study. Gynecol Oncol. 2017;147(2):257–61.
da Costa MV, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132(2):287–91.
Medina-Franco H, Cortes-Gonzalez R, Lambreton-Hinojosa F, Fimbres-Morales A, Vargas-Siordia JC. Neoadjuvant chemotherapy increases R0 cytoreduction rate but does not improve final outcome in advanced epithelial ovarian cancer. Ann Surg Oncol. 2017;24(5):1330–5.
Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135(2):223–30.
Bohm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457–63.
Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, et al. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. Histopathology. 2018;72(4):619–25.
Cohen PA, Powell A, Bohm S, Gilks CB, Stewart CJR, Meniawy TM, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441–8.
Conflict of interest
The authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gupta, A., Kumar, D., Kaushal, V. et al. Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India. Indian J Gynecol Oncolog 18, 38 (2020). https://doi.org/10.1007/s40944-020-00391-x
- Epithelial ovarian cancers
- Neoadjuvant chemotherapy
- Interval debulking surgery